Chevy Chase Trust’s Acceleron Pharma XLRN Stock Holding History

Chevy Chase Trust’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-675	Closed	-$36K	–	1108
2019 Q4	$36K	Buy	+675	New	+$30.8K	﹤0.01%	904

Other funds holding XLRN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Chevy Chase Trust's XLRN Position: Q1 2020 in Review

Chevy Chase Trust sold out of Acceleron Pharma (XLRN) in Q1 2020, closing a stake of 675 shares — an estimated $36K sold.

Chevy Chase Trust first reported a position in XLRN in Q4 2019 and held it in 1 quarter. The position peaked at $36K in Q4 2019. 217 funds tracked by Wall St. Rank hold XLRN as of Q1 2020.

Chevy Chase Trust reported no remaining Acceleron Pharma position as of Q1 2020 after selling out during the quarter.
Chevy Chase Trust sold 675 Acceleron Pharma shares in Q1 2020, an estimated $36K.
Chevy Chase Trust first reported a position in Acceleron Pharma in Q4 2019 and held it in 1 quarter.
Chevy Chase Trust's Acceleron Pharma position peaked at $36K in Q4 2019.
217 funds tracked by Wall St. Rank held Acceleron Pharma as of Q1 2020.

Based on Chevy Chase Trust's 13F filing for Q1 2020, filed 13 May 2020.